Newsfeeds Archive - Spark Newswire

3 minute read

World’s Largest Psychedelics Conference Sheds Light On Alternative Mental Health Therapies, Boasts 12K Attendees

June 26, 5:06 PM

The Multidisciplinary Association for Psychedelic Studies (MAPS) sponsored a Psychedelic Science conference in Denver last week, which gathered over 12,000 people from the entire psy

KONEF

5 minute read

Psyched: Next-Gen Compounds For Depression, Congress, Rescheduling, Benzinga Psychedelics Conference & More

By Lara Goldstein

March 13, 5:13 PM

Major Depressive Disorder: Small Pharma’s Phase 2 DMT Trial, BetterLife’s Preclinical LSD Trial

ATAI

2 minute read

Another Company Approved To Begin Production Of Psychedelics Under Canadian Dealers License

By Lara Goldstein

March 9, 1:17 PM

A Contract Research Organization (CRO) and a wholly-owned subsidiary of Wellbeing Digital Sciences Inc.

KONEF

3 minute read

Who’s Who At The Benzinga Psychedelics Capital Conference? Check Out These CEOs & Meet Them In Person

By Lara Goldstein

March 8, 6:58 PM

This year’s edition of the Benzinga Psychedelics Capital Conference, THE place to be for those interested or already involved in the space, will take place on April 13, following our established Cannabis Capital Confere

BWVI

6 minute read

Psyched: Four New States With Reform Bills, Psilocybin For Genetic Disorders And Functional Neurological Disorder, Struggle For Access & More

By Lara Goldstein

February 21, 6:19 PM

Psychedelics States Reform: Utah, Iowa, Missouri and Oklahoma’s New Bills; Hawaii, Arizona and Washington's Green Lights, New Hampshire's Setback Earlier this week, three bills were introduced and added to the list of measures calling for some sort of psychedelics legalization, while some of the already filed ones continue progressing and others get a thumbs down.

AGNPF

2 minute read

Health Canada Grants Exemption: Phase 2 Trial On Psilocybin For Genetic Disorder

By Lara Goldstein

February 14, 2:37 PM

Wellbeing Digital (OTC: KONEF) subsidiary KGK Sciences will advance with the first-ever Phase 2a clinical trial assessing repetitive, oral microdose psilocybin therapy for Fragile X Syndrome (FXS), a genetic disorder.

KONEF

3 minute read

Women’s Footprint In Psychedelics Is Undeniable, Benzinga’s Psychedelics Advisory Council’s Six New Trailblazers

By Lara Goldstein

January 30, 1:50 PM

In its capacity as a financial news and media outlet, Benzinga has added six new members to its Psychedelics Advisory Council.

KONEF

2 minute read

First-Ever Clinical Trial On Magic Mushroom Therapy For Autism’s Genetic Cause Receives Approval

By Lara Goldstein

December 27, 1:47 PM

The partnership leading the way on psilocybin therapy for Fragile X Syndrome (FXS), the major genetic cause of Autism Spectrum Disorder (ASD), has received approval from Health Canada in the form of a No Objection letter and is set to proceed with the first-ever Phase 2a clinical trial on the magic mushrooms therapy for this condition.

KONEF

4 minute read

Psyched: Fed Guidelines And Research Production Quotas, Protests In Canada, Cal’s Decrim Project

By Lara Goldstein

December 6, 3:20 PM

Psychedelic Research & Fed Funding By The National Institute Of Mental Health The National Institute of Mental Health (NIMH) named the types of psychedelics studies to which it would grant funds and further guidance for pre-clinical research and studies with young participants.

AWKNF